Wuhan-Based Female Scientist Dr. Wei Jun Raises Nearly RMB 5 Billion in One Month, Files IPO Prospectus

On July 2, iRegene Therapeutics officially announced the completion of its C+ round financing of RMB 260 million.

In this round, Chengdu Sci-Tech Innovation Investment served as the lead investor, with joint participation from institutions including CSC Financial Capital, Wuxi Venture Capital, Dingtai Star, Xinjiye, and Hony Capital. Existing shareholders Yuanxi Haihe and GSR United Runpuyuanfeng also made additional investments.

Notably, just one month ago in early June 2026, the company had just completed a RMB 210 million financing round.

The successive completion of two major funding rounds within a short period fully reflects the high confidence of both new and existing investors in iRegene Therapeutics’ technological pathway and clinical prospects.

This financing pace also marks iRegene Therapeutics’ entry into a critical transition period—moving from “technology platform validation” to a new stage of “clinical value realization” and “accelerated capitalization.”

iRegene Therapeutics was founded in Wuhan in 2017 by Dr. Wei Jun, a returning overseas scientist, focusing on the research and development of small-molecule chemical transcription regulation-induced pluripotent stem cell (iPSC)-derived products.

Dr. Wei possesses a robust clinical and research background: he previously served as a resident physician at the Stem Cell Center of Union Hospital, affiliated with Huazhong University of Science and Technology; later, he joined the Roslin Institute in the UK as a Senior Research Fellow in embryonic stem cells, and served as an Expert-level R&D Lead at Axol Bioscience in the UK, while concurrently holding a position as Visiting Researcher in Clinical Neuroscience at the University of Cambridge. He has accumulated over 20 years of experience in the fields of functional genomics in developmental biology and stem cell-based disease modeling.

In 2017, he returned to China to start a business, and his project received key funding from the Ministry of Human Resources and Social Security’s “Startup Support Program for Returned Overseas Students.”

The company has independently established a comprehensive iPSC product development platform based on AI-driven screening of small-molecule compounds as inducers and culture media, aiming to achieve efficient and directed differentiation of pluripotent stem cells into target cell types.

Reviewing its financing journey, iRegene Therapeutics has continuously received capital support: In January 2022, it completed a nearly RMB 100 million Series A+ round (led by Changjiang Securities Innovation Investment); in October 2024, it completed a Series B round exceeding RMB 100 million (co-led by Ceyuan Capital and Guosheng Capital, with participation from multiple industrial investors); in April 2025, it completed a nearly RMB 100 million Series B+ round (led by Fengchuan Capital, with participation from Hetang Venture Capital); and in September 2025, it again completed a Series B round exceeding RMB 300 million (jointly invested by Northern Light Venture Capital, Chuangjing Capital, Yuanxi Haihe, and others).

Currently, the company’s core pipeline has entered dual-track clinical validation in China and the United States, with multiple investigational products advancing concurrently. Notably, the Parkinson’s disease cell therapy product NouvNeu001 has been granted Fast Track Designation (FTD) and Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. FDA.

On March 16, 2026, all subjects in the Phase II clinical trial of NouvNeu001 in China completed dosing; meanwhile, the first patient in the U.S. Phase II trial was dosed on February 11, 2026.

Another key pipeline asset, the NouvNeu004 injection for multiple system atrophy (MSA), has also achieved a milestone breakthrough: on October 23, 2025, it received approval from China’s National Medical Products Administration (NMPA) to conduct full-cycle Phase I–III clinical trials; subsequently, on November 26, 2025, the U.S. Food and Drug Administration (FDA) granted the product “Special Exemption” status and formally approved its international Phase I clinical trial.

Furthermore, the NouvSight ophthalmic pipeline is also progressing steadily.

To date, iRegene Therapeutics has evolved from a single-product-driven model to gradually building a clinical asset portfolio covering multiple indications, with its internationalization and pipeline synergies becoming increasingly prominent.